<DOC>
	<DOCNO>NCT02475122</DOCNO>
	<brief_summary>Portal hypertension ( PHT ) lead esophageal varix clinically present , time diagnosis , 60 % cirrhotic patient ( Groszmann NEJM 2005 ) . Variceal bleed life-threatening complication . The yearly incidence first variceal bleed cirrhotic patient estimate 4 % . This risk increase 15 % medium large varix initially present , ( D'amico Baillieres Clin Gastroenterol 1997 ) ; Therefore , patient medium large varix primary prophylaxis treatment nonselective beta-blockers must institute decrease risk bleed approximately half ( d'amico Hepatology 2005 ) . The method evaluate efficacy beta blocker treatment hepatic venous pressure gradient ( HVPG ) . HVPG &lt; 12 mmHg decrease HVPG 20 % beta blocker treatment reduce dramatically risk bleeding ( Feu F. Lancet 1995 ) . But good response ( HVPG &lt; 12 mmHg reduction &gt; 20 % ) beta blocker observe almost 30 % patient . In non responder patient , variceal bleed incidence estimate 24 % 2 year . In situation , alternative treatment beta-blockers suggest : endoscopic ligation , show effective beta blocker primary prevention , recently carvedilol ( Reiberger , Gut 2012 ) . So , HVPG monitoring may provide critical information patient . However , technical requirement invasivity , HVPG measurement feasible clinical practice . So , general consensus continue indefinitely beta blocker treatment without control hemodynamic efficiency ( merkel J. Hepatology 2009 ) . Previous study suggest interest azygos blood flow measurement evaluate hemodynamic change esophageal collateral vessel patient portal hypertension ( Bosch J. Hepatology 1985 ) . More recently Magnetic Resonance Imaging ( MRI ) report efficient technique ass azygos blood flow ( Gouya Radiology 2011 ) cirrhotic patient . Its feasibility obviously high HVPG measurement . However , way HVPG , large-scale implementation clinical practice azygos blood flow measurement MRI require specify minimal absolute threshold , relative post-therapeutic decrease , related variceal bleeding .</brief_summary>
	<brief_title>Prognostic Value Measuring DsAz MRI Cirrhotic Patients Prophylactic Treatment With β Blocker ( AzyMR )</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Gastric Varices</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<criteria>Cirrhotic patient require β blocker primary prophylaxis bleed esophageal varix Patients 18 year 's old life expectancy le one month Patient already vasoactive treatment patient CHC portal vein thrombosis patient without social security deprive freedom contraindication MRI contraindication betablockers mental state allow sign informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Measurement azygos blood flow</keyword>
</DOC>